Inflammation, coronary artery disease, and hormones

Menopause

Volumn 15, Issue 6, 2008, Pages 1036-1038

  Lobo, Rogerio A ^a  

^a Medical Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTROGEN; GELATINASE B; HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE; MONOCYTE CHEMOTACTIC PROTEIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOCARDIOGRAPHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CYTOKINE PRODUCTION; EDITORIAL; GENE EXPRESSION; INFLAMMATION; METABOLIC SYNDROME X; POSTMENOPAUSE; BLOOD; CORONARY ARTERY DISEASE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; IMMUNOLOGY; NOTE;

CORONARY ARTERY DISEASE; E-SELECTIN; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; MEDROXYPROGESTERONE 17-ACETATE; POSTMENOPAUSE; VASCULAR CELL ADHESION MOLECULE-1;

EID: 63349091049     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318184c45a     Document Type: Editorial

References (39)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;3:115-126.
2. Koh KK. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc Res 2002;55:714-726.
3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
4. Demerath E, Towne B, Blangero J, Siervogel RM. The relationship of soluble ICAM-1, VCAM-1, P-selectin, E-selectin to cardiovascular disease risk factors in healthy men and women. Ann Hum Biol 2001;28:664-678.
5. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997;96:4219-4225.
6. Chu M, Cushman M, Solomon R, Lobo RA. Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers [published online ahead of print May 27, 2008]. Am J Obstet Gynecol 2008.DOI: 10.1016/j.ajog.2008.04.033.
7. Harnish DC, Scicchitano MS, Adelman SJ, Lyttle CR, Karathanasis SK. The role of CBP in estrogen receptor cross-talk with nuclear factor kB in HepG2 cells. Endocrinology 2000;141:3403-3411.
8. Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996;98:36-42.
9. Miller AP, Feng W, Xing D, et al. Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries. Circulation 2004;110:1664-1669.
10. Pervin S, Singh, Rosenfeld ME, et al. Estradiol suppresses MCP-1 expression in vivo: implications for atherosclerosis. Arterioscler Thromb Vasc Biol 1998;18:1575-1582.
11. Srivastava S, Weitzmann MN, Cenci S, et al. Estrogen decreases TNF gene expression by blocking NJK activity and the resulting production of c-Jun and JunD. J Clin Invest 1999;104:503-513.
12. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins. The Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 1999;100:717-722.
13. Vehkavaara S, Silveira A, Hakala-ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-625.
14. Herrington DM, Brosnihan KB, Pusser BE, et al. Differential effects of estrogen and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001;86:4216-4222.
15. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 2002;105:1436-1439.
16. Lamon-Fava S, Posfai B, Schaefer EJ. Effect of hormonal replacement therapy on C-reactive protein and cell-adhesions molecules in postmenopausal women. Am J Cardiol 2003;91:252-254.
17. Koh KK, Bui MN, Mincemoyer, Cannon RO III. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol 1997;80:1505-1507.
18. Koh KK, Blum A, Hathaway L, et al. Vascular effects of estrogen and vitamin E therapies in postmenopausal women. Circulation 1999;100:1851-1857.
19. Koh KK, Jin DK, Yang SH, et al. Vascular effects of synthetic or natural progestogen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 2001;103:1961-1966.
20. Stork S, Baumann K, von Schacky C, Angerer P. The effect of 17 beta-estradiol on MCP-1 serum levels in postmenopausal women. Cardiovasc Res 2002;53:642-649.
21. Koh KK, Son JW, Jin DK, et al. Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels. Int J Cardiol 2001;81:43-50.
22. Walsh BW, Cox DA, Sashegyi A, et al. Role of tumor necrosis factor-α and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 2001;88:825-828.
23. Koh KK, Ahn JY, Jin DK, et al. Effects of continuous combined hormone replacement therapy on inflammation in hypertensive and/or overweight postmenopausal women. Arterioscler Thromb Vasc Biol 2002;22:1459-1464.
24. Cushman M, Meilahn EN, Psaty BM, et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999;19:893-899.
25. Salpeter SR, Walsh JM, Orniston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538-554.
26. Yeboah J, Klein K, Brosnihan B, Reboussin D, Herrington D. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease. Menopause 2008;15:1060-1064.
27. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529.
28. Herrington DM, Espeland MA, Crouse JR 3rd, et al. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol 2001;21:1955-1961.
29. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences [review]. Science 2005;308(5728):1583-1587.
30. Post WS, Goldschmidt-Clermont PJ, Wilide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999;43:985-991.
31. Umetani M, Domoto H, Gormley AK, et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med 2007;13:1185-1192.
32. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
33. Manson JF, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
34. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-365.
35. Sumino H, Ichikawa S, Kasama S, et al. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Hypertens Res 2005;28:579-584.
36. Decensi A, Omodei U, Robertson C, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 2002;106:1224-1228.
37. Modena MG, Bursi F, Fantini G, et al. Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen. Am J Med 2002;113:331-334.
38. Lewandowski KC, Komorowski J, Mikhalidis DP, et al. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J Clin Endocrinol Metab 2006;91:3123-3130.
39. Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000;36:1797-1802.